Drug Profile
Research programme: claudin antagonists - Adherex Technologies
Latest Information Update: 23 Feb 2011
Price :
$50
*
At a glance
- Originator Adherex Technologies
- Class
- Mechanism of Action Cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Aug 2006 No development reported - Preclinical for Cancer in Canada (unspecified route)
- 18 May 2004 Preclinical trials in Cancer in Canada (unspecified route)